The European Commission has approved AstraZeneca’s (NYSE:AZN) PARP inhibitor Lynparza (olaparib) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer.
About 5-7% of metastatic pancreatic cancer patients have such a germline mutation.
Lynparza is approved in the U.S. and several other countries as first-line maintenance treatment for these patients.
https://seekingalpha.com/news/3589368-astrazenecas-lynparza-okd-in-europe-for-brca-pancreatic-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.